133 related articles for article (PubMed ID: 15744338)
1. Acute myeloid leukemias with recurrent genetic abnormalities: frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy.
Doubek M; Brychtova Y; Berkovcova J; Krejci M; Palasek I; Dvorakova D; Mayer J
Leukemia; 2005 May; 19(5):885-8. PubMed ID: 15744338
[No Abstract] [Full Text] [Related]
2. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.
Guièze R; Renneville A; Cayuela JM; Abdelali RB; Boissel N; de Botton S; Rubio MT; Mazingue F; Macintyre EA; Cheok M; Sigaux F; Fenaux P; Dombret H; Preudhomme C
Leukemia; 2010 Jul; 24(7):1386-8. PubMed ID: 20508610
[No Abstract] [Full Text] [Related]
3. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
[TBL] [Abstract][Full Text] [Related]
4. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
Foroni L; Harrison CJ; Hoffbrand AV; Potter MN
Br J Haematol; 1999 Apr; 105(1):7-24. PubMed ID: 10366253
[No Abstract] [Full Text] [Related]
5. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
6. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
7. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
8. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
[No Abstract] [Full Text] [Related]
9. Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation.
Testoni N; Martinelli G; Zaccaria A; Miggiano MC; Pelliconi S; Visani G; Manfroi S; Gherlinzoni F; Mangianti S; Tura S
Bone Marrow Transplant; 1996 Dec; 18(6):1141-5. PubMed ID: 8971385
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostics and therapy of acute myeloid leukemia].
Kern W; Haferlach T; Schoch C; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(42):2208-13. PubMed ID: 12397550
[No Abstract] [Full Text] [Related]
12. Curing acute myelogenous leukemia: still a major challenge.
Smith BD; Karp JE
Leuk Res; 2005 Jun; 29(6):607-8. PubMed ID: 15863198
[No Abstract] [Full Text] [Related]
13. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
14. Der(1;16)(q10;p10) in acute myeloid leukemia: the first female case described.
Kokalj Vokac N; Zagorac A; Erjavec Skerget A; Roskar Z; Podgornik H; Cernelc P
Acta Haematol; 2008; 119(1):54-6. PubMed ID: 18268405
[No Abstract] [Full Text] [Related]
15. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
18. Monitoring minimal residual disease in AML: the right time for real time.
Jaeger U; Kainz B
Ann Hematol; 2003 Mar; 82(3):139-47. PubMed ID: 12634945
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
Pullarkat V; Aldoss I
Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]